賽里斯治療 MCRB 深 滬
已收盤 05-08 16:00:00 美东时间
7.70
-0.020
-0.26%
華盛通- 最 高7.8699
- 今 開7.70
- 成交量 2.79万股
- 最 低 7.50
- 昨 收 7.72
- 總市值 7456.63万
- 52周最高 29.98
- 市盈率 靜 11.99
- 換手率 0.29%
- 52周最低 6.5601
- 委 比 85.71%
- 總股本 968.39万
- 歷史最高 1040.00
- 量 比 0.41
- 振 幅 4.79%
- 歷史最低 6.5601
- 每 手 1
- 風險率 4.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over earnings of $3.75 per share
05-05 19:14
Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform
05-04 19:06
Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21
Presentations DetailsPoster Presentation (Abstract 1726)Title: Effect of investigational, live biotherapeutic, SER-155, on gastrointestinal (GI) microbiome composition in adults receiving allogeneic haematopoietic stem
04-20 19:07
Seres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics将在2026年CARB-X投资者日展示其对抗抗药性细菌的进展。公司获得360万美元资助，用于开发液体生物治疗剂SER-428，适用于无法口服胶囊的高风险患者。Seres与哥伦比亚大学合作设计临床试验，并继续开发SER-155和SER-603，分别针对干细胞移植和肠易激综合征。公司强调与CARB-X的合作对其抗击抗药性至关重要，并计划进一步发展其生物治疗平台。
04-09 11:00
Seres Therapeutics posts 2025 profit as expenses fall
Seres Therapeutics posts 2025 profit as expenses fall Overview US biotechnology firm's 2025 net income from continuing ops was $5.7 mln, reversing prior loss 2025 revenue was $789,000 as company focused on early-stage pipeline and transition services Seres cut R&D and G&A expenses yr/yr as it priori
03-12 19:14
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of $(1.60) per share from
03-12 19:10
BRIEF-Seres Therapeutics FY EPS USD 0.64
BRIEF-Seres Therapeutics FY EPS USD 0.64 Mar 12 (Reuters) - Seres Therapeutics FY collaboration revenue USD 789 thousand. FY operating expenses USD 94.76 million FY net income USD 5.696 million FY operating income USD -93.971 million
03-12 19:00
